The Gleasmans were idea men first, not businessmen. They invented without thinking about scale and competition, often. With Kaplan, the 2 potential technologies that were identified to pursue to commercialization were the Isotorque differential and the hydraulic pump & motor. Well, I guess that's 3 products, come to think of it. Then they pivoted more than partially and added the MyCadian Cura alertness/fatigue measurement. MyCadian Cura Z Coach are products now. Pump & motor are alive in development, and thus far well. Isotorque is sidelined, at best.
Ultimately, stakeholders are rewarded when a company generates cash and becomes profitable. Ordinarily, a stock might get the benefit of the doubt for future prospects unless, of course, shorts -- and particularly evil, naked shorts -- mark them for death prematurely. Then, no benefit of the doubt. Gotta produce definitively, or else.
In my mind, I am certain of the naked short. And, Sulax, I never expect you to acknowledge it. And nothing about this is too funny.
News 
Market Data 
Discover 
